AstaBead® (Astaxanthin Beadlet)

Haematococcus pluvialis
Evidence Level
Preliminary
0 Clinical Trials
4 Documented Benefits
1/5 Evidence Score

AstaBead® is a beadlet form of natural astaxanthin launched in 2022 by Divi's Nutraceuticals, which turns astaxanthin oleoresin from the Icelandic producer Algalif into beadlets. Algalif makes its astaxanthin from the microalga Haematococcus pluvialis. The beadlets contain 5% astaxanthin and come as a form that can be pressed directly into tablets, capsules and bars and as a fast-dispersing form for powdered drinks. No published human trial naming AstaBead or Algalif astaxanthin was found in PubMed or ClinicalTrials.gov. The pooled skin trials, the eye-strain trials of two other brands and the pooled oxidative stress trials used other products, so NutraSmarts lists AstaBead under no health category.

Studied Dose No dose of AstaBead has been tested in a published human trial. EFSA judged 8 mg of astaxanthin a day from supplements, on top of the usual diet, safe for adults; children aged 10 to under 14 would exceed its acceptable daily intake at that level.
Active Compound Natural astaxanthin oleoresin from Haematococcus pluvialis microalgae (Algalif, Iceland), formulated by Divi's Nutraceuticals into beadlets containing 5% astaxanthin.

Benefits

Beadlet form and algae source

AstaBead turns Algalif's Haematococcus astaxanthin oleoresin into 5% beadlets: one form can be pressed directly into tablets without oil seeping out or discoloring, and a fast-dispersing form is meant for powdered drinks. These are handling features reported by the companies; no study has compared absorption from AstaBead with other forms.

Skin moisture and elasticity: trials used other products

A pooled analysis of eight small randomized trials found better skin moisture and elasticity, but not wrinkle depth, with oral astaxanthin versus control. All of the trials used Haematococcus astaxanthin from other products, not the AstaBead beadlet, so the result is not credited to AstaBead; see the Astaxanthin page.

Screen-related eye strain: studied with two other brands

Both placebo-controlled eye trials cited here used branded algae astaxanthin with its own page. In 64 children, 4 mg a day of AstaReal for 84 days lowered eye-strain questionnaire scores more than placebo in a maker-run trial. In 60 adults doing screen work, 9 mg a day of astaxanthin from BGG, the maker of AstaZine, did not change visual acuity, the main outcome, overall. Neither tested AstaBead.

Oxidative stress markers: pooled trials of other products

A pooled analysis of 12 placebo-controlled trials (380 people) of various astaxanthin products found lower blood malondialdehyde, a marker of fat oxidation; an earlier analysis of 9 trials found only a borderline difference. No trial of AstaBead measured oxidative stress, so this is not credited to it.

Mechanism of action

1

Platelets and clotting (animal and cell studies)

In rats and mice given astaxanthin by mouth, and in human platelets and liver cells, astaxanthin reduced platelet aggregation and suppressed blood clotting by lowering the liver's production of clotting factors. These are laboratory and animal findings, not results in people taking AstaBead.

2

Inflammation markers in pooled trials of other products

A pooled analysis of 12 placebo-controlled trials found lower IL-6 only in people with type 2 diabetes, while C-reactive protein and TNF-alpha did not change. None of the trials used AstaBead.

Clinical trials

Side effects and drug interactions

Common Potential side effects

No human safety study of AstaBead itself was found in PubMed.
EFSA judged 8 mg of astaxanthin a day from supplements, on top of the usual diet, safe for adults, but found that children aged 10 to under 14 would exceed its acceptable daily intake at that level.
Pregnancy and breastfeeding have not been studied.

Important Drug interactions

In rats, mice and human platelets and liver cells, astaxanthin reduced platelet aggregation and blood clotting, and one case report linked astaxanthin to a sharp INR rise and bruising in a woman taking warfarin and aspirin, so check with a doctor before use if you take blood thinners or antiplatelet medicines.

Frequently asked questions about AstaBead® (Astaxanthin Beadlet)

Is AstaBead natural or synthetic?

AstaBead is made from natural astaxanthin oleoresin from Haematococcus pluvialis microalgae, supplied by Algalif in Iceland and formed into beadlets by Divi's Nutraceuticals. No published human trial has tested AstaBead itself.

What is AstaBead?

AstaBead® is a beadlet form of natural astaxanthin launched in 2022 by Divi's Nutraceuticals, which turns astaxanthin oleoresin from the Icelandic producer Algalif into beadlets. Algalif makes its astaxanthin from the microalga Haematococcus pluvialis.

What is AstaBead used for?

NutraSmarts does not list AstaBead under a health category. What the research covers: AstaBead turns Algalif's Haematococcus astaxanthin oleoresin into 5% beadlets: one form can be pressed directly into tablets without oil seeping out or discoloring, and a fast-dispersing form is meant for powdered drinks.

What is the recommended dosage of AstaBead?

No dose of AstaBead has been tested in a published human trial. EFSA judged 8 mg of astaxanthin a day from supplements, on top of the usual diet, safe for adults; children aged 10 to under 14 would exceed its acceptable daily intake at that level. Always follow the product label and check with a healthcare provider for personal advice.

Is AstaBead safe, and does it have side effects?

Side effects and cautions reported for AstaBead include: No human safety study of AstaBead itself was found in PubMed. EFSA judged 8 mg of astaxanthin a day from supplements, on top of the usual diet, safe for adults, but found that children aged 10 to under 14 would exceed its acceptable daily intake at that level. It may also interact with some medications. AstaBead is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does AstaBead interact with any medications?

Possible interactions include: In rats, mice and human platelets and liver cells, astaxanthin reduced platelet aggregation and blood clotting, and one case report linked astaxanthin to a sharp INR rise and bruising in a woman taking warfarin and aspirin, so check with a doctor before use if you take blood thin… If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for AstaBead?

NutraSmarts rates the evidence for AstaBead as Preliminary (1 out of 5). It is backed by 10 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(10 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Krawiec S (Nutritional Outlook). Divi's Nutraceuticals and Algalif launch AstaBead, concentrated astaxanthin beadlets. Nutritional Outlook. 2022;Trade press article, 9 May 2022, accessed 2026-11-14..SourceUsed to support: Not PubMed-indexed. Trade press report, used for identity only: Algalif (Iceland) supplies astaxanthin oleoresin naturally sourced from microalgae, which Divi's Nutraceuticals converts into AstaBead beadlets containing 5% astaxanthin, in a directly compressible form for tablets, hard capsules and bars and a fast-dispersing form for powdered drinks. No human studies are mentioned.
  2. Sivasubramaniam K (NutraIngredients). Algalif plans expansion as it celebrates tenth anniversary. NutraIngredients. 2022;Trade press article, 20 May 2022, accessed 2026-11-14..SourceUsed to support: Not PubMed-indexed. Trade press report, used for identity only: Algalif provides ingredients and finished products from Haematococcus pluvialis microalgae, including astaxanthin oleoresins, bulk capsules and spray-dried algal biomass.
  3. Zhou X, Cao Q, Orfila C, Zhao J, Zhang L. Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing. Nutrients. 2021;13(9):2917. doi: 10.3390/nu13092917.PubMedUsed to support: Other-product reference (pooled analysis of many astaxanthin products; see the Astaxanthin page): Review of nine randomized trials of oral astaxanthin for skin aging, all using Haematococcus pluvialis astaxanthin (eight pooled, 16 to 65 people each, 2 to 12 mg/day for 4 to 16 weeks, middle-aged participants with signs of skin aging; two trials paired 2 mg astaxanthin with collagen or tocotrienol): skin moisture (SMD 0.53; I2 52%) and elasticity (SMD 0.77; I2 75%) improved significantly versus control (placebo, or rosehip powder in two trials), but wrinkle depth did not (SMD -0.26). The pooled trials include AstaReal and FUJIFILM studies, among others. Its introduction notes that natural astaxanthin occurs mainly as mono- or diesters. A PubMed check of the astaxanthin trials in its reference list found none marked as retracted. It did not test AstaBead.
  4. Hecht KA, Marwah M, Wood V, Nishida Y, Bach AE, Gerson J, Hom MM, Schnackenberg J, Raote S, Srivastava S, Negi P, Caston E. Astaxanthin (AstaReal(®)) Improved Acute and Chronic Digital Eye Strain in Children: A Randomized Double-Blind Placebo-Controlled Trial. Adv Ther. 2025;42(4):1811-1833. doi: 10.1007/s12325-025-03125-7.PubMedUsed to support: Other-product reference (AstaReal; see the AstaReal page): randomized, double-blind trial in 64 children aged 10 to 14 with at least 4 hours of daily screen time and mild to moderate computer vision syndrome symptoms. 4 mg/day astaxanthin for 84 days improved computer-vision-syndrome questionnaire scores, the primary outcome (-4.00 vs -1.72 with placebo), and visual-fatigue scores versus placebo, with no between-group difference in visual acuity, tear production (Schirmer test), near point of accommodation or safety measures. Seven of the 12 authors were current or former employees of Fuji Chemical and its AstaReal subsidiaries, and two worked for the contract research organization Fuji engaged. It did not test AstaBead.
  5. Sekikawa T, Kizawa Y, Li Y, Miura N. Effects of diet containing astaxanthin on visual function in healthy individuals: a randomized, double-blind, placebo-controlled, parallel study. J Clin Biochem Nutr. 2023;72(1):74-81. doi: 10.3164/jcbn.22-65.PubMedUsed to support: Other-product reference (BGG Haematococcus astaxanthin; see the AstaZine page): BGG-sponsored randomized, double-blind trial in 60 healthy adults doing regular screen work. 9 mg/day for 6 weeks did not change visual acuity, the primary outcome, in the full sample; corrected acuity after screen work was better preserved than with placebo only in participants aged 40 and over (p<0.05), and functional visual acuity and pupil constriction did not differ. It did not test AstaBead.
  6. Ma B, Lu J, Kang T, Zhu M, Xiong K, Wang J. Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials. Nutr Res. 2022;99:40-50. doi: 10.1016/j.nutres.2021.09.005.PubMedUsed to support: Other-product reference (pooled analysis of many astaxanthin products; see the Astaxanthin page): Systematic review and meta-analysis of 12 placebo-controlled randomized trials (380 participants): blood malondialdehyde fell versus placebo (SMD -0.95; 95% CI -1.67 to -0.23), significantly in the type 2 diabetes subgroup; few trials measured other oxidative markers; IL-6 fell in type 2 diabetes, while C-reactive protein and TNF-alpha did not change. The authors declared no conflicts of interest. It did not test AstaBead.
  7. Wu D, Xu H, Chen J, Zhang L. Effects of Astaxanthin Supplementation on Oxidative Stress. Int J Vitam Nutr Res. 2020;90(1-2):179-194. doi: 10.1024/0300-9831/a000497.PubMedUsed to support: Other-product reference (pooled analysis of many astaxanthin products; see the Astaxanthin page): Systematic review and meta-analysis of 9 randomized controlled trials (searches 1948 to 2015): the between-group effect on malondialdehyde was borderline (p = 0.050), and the authors judged the data insufficient and the antioxidant effect of astaxanthin in humans unclear. Within the astaxanthin groups, malondialdehyde and isoprostane fell and superoxide dismutase and total antioxidant capacity rose versus baseline; doses of 20 mg a day or more showed effects on some markers, lower doses did not. It did not test AstaBead.
  8. Zhang L, Luo Y, Lei N, Chen S, Lv K, Xiang H, Tang Z, Li B, Zheng X, Li S, Wang X, Li M, Liu H, Zhang B, Wang J, Xu X, Fang C. Astaxanthin suppresses thrombosis by inhibiting both platelet activation and blood coagulation. Br J Pharmacol. 2026;183(11):2890-2912. doi: 10.1111/bph.70363.PubMedUsed to support: Rat, mouse and cell study: astaxanthin given by mouth (gavage) to rats and mice, and added to human platelets and liver cells, reduced platelet aggregation, adhesion and activation and suppressed both extrinsic and intrinsic blood coagulation by lowering the liver's production of clotting factors. Laboratory and animal data, not a human drug-interaction study, and it did not test any named product.
  9. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Engel KH, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Sanz Y, Schlatter JR, van Loveren H, Ackerl R, Gelbmann W, Steinkellner H, Knutsen HK. Safety of astaxanthin for its use as a novel food in food supplements. EFSA J. 2020;18(2):e05993. doi: 10.2903/j.efsa.2020.5993.PubMedUsed to support: EFSA opinion: using an acceptable daily intake of 0.2 mg/kg body weight, combined intake of astaxanthin from the background diet (fish and crustaceans) plus 8 mg a day from food supplements is safe for adults, while adolescents aged 14 to under 18 reach the acceptable daily intake and it is exceeded by 28% in children aged 10 to under 14 and by up to 524% in infants aged 4 to 6 months. The earlier 2014 assessment it updates concerned astaxanthin from Haematococcus pluvialis.
  10. Santiyanon N, Yeephu S. Interaction between warfarin and astaxanthin: A case report. J Cardiol Cases. 2019;19(5):173-175. doi: 10.1016/j.jccase.2019.01.002.PubMedUsed to support: Single case: a 69-year-old woman on stable warfarin developed bruising and an INR rise from 1.4 to 10.38 after starting astaxanthin; causality was rated probable.